Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.

Manz M, Beglinger C, Vavricka SR.

Gut. 2009 Jan;58(1):149. doi: 10.1136/gut.2008.161638. No abstract available.

2.

Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.

Jordan N, Waghmare A, Abi-Ghanem AS, Moon A, Salvatore CM.

J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):294-6. doi: 10.1097/MPG.0b013e31822938c3. No abstract available.

PMID:
21694635
3.

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X; RATIO group.

Ann Rheum Dis. 2011 Apr;70(4):616-23. doi: 10.1136/ard.2010.137422. Epub 2010 Dec 21.

PMID:
21177290
4.

Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.

Mañosa M, Domènech E, Marín L, Olivé A, Zabana Y, Cabré E, Gassull MA.

Gut. 2008 Apr;57(4):559; author reply 559-60. No abstract available.

PMID:
18334664
5.

First case report of adalimumab-induced psoriasis in Crohn's disease.

Harris MD, Richards R.

Am J Gastroenterol. 2009 Mar;104(3):792-3. doi: 10.1038/ajg.2008.101. Epub 2009 Feb 3. No abstract available.

PMID:
19262532
6.

Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.

Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH.

J Gastroenterol Hepatol. 2010 Nov;25(11):1732-8. doi: 10.1111/j.1440-1746.2010.06407.x.

PMID:
21039834
7.

Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.

Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J.

Eur J Heart Fail. 2009 Nov;11(11):1106-9. doi: 10.1093/eurjhf/hfp132.

8.

Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.

Nancey S, Boschetti G, Cotte E, Cathey-Javouhay A, Laidet M, Chichery A, Francois Y, Glehen O, Flourié B.

Inflamm Bowel Dis. 2011 Apr;17(4):1060-1. doi: 10.1002/ibd.21433. Epub 2010 Oct 25. No abstract available.

PMID:
21391289
9.

Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.

Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE.

Gut. 2008 Mar;57(3):425; author reply 425-6. doi: 10.1136/gut.2007.132407. No abstract available.

PMID:
18268059
10.

Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.

Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J.

Inflamm Bowel Dis. 2010 Oct;16(10):1634-6. doi: 10.1002/ibd.21198. No abstract available.

PMID:
20027647
11.

Invasive pulmonary aspergillosis associated with infliximab therapy.

Warris A, Bjørneklett A, Gaustad P.

N Engl J Med. 2001 Apr 5;344(14):1099-100. No abstract available.

PMID:
11291675
12.

Mycobacterium chelonae infection associated with adalimumab therapy.

Díaz F, Urkijo JC, Mendoza F, de la Viuda JM, Blanco M, Unzurrunzaga A, Ayarza R.

Scand J Rheumatol. 2008 Mar-Apr;37(2):159-60. doi: 10.1080/03009740701716876. No abstract available.

PMID:
18415777
13.

[Adalimumab in Crohn's disease - data from real life].

López San Román A, Van Domselaar M, Garrido E.

Rev Esp Enferm Dig. 2008 Nov;100(11):671-5. Spanish. No abstract available.

14.

Varicella zoster exposure in patients with inflammatory bowel disease--recall is not enough.

Aggarwal D, Limdi JK.

Am J Gastroenterol. 2014 Mar;109(3):448-9. doi: 10.1038/ajg.2013.378. No abstract available.

PMID:
24594962
15.

Safety and efficacy of adalimumab in pediatric patients with Crohn disease.

Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L.

J Pediatr Gastroenterol Nutr. 2008 Jul;47(1):19-25. doi: 10.1097/MPG.0b013e318174e886.

PMID:
18607264
16.

[Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy].

Salavert M, Bastida G, Pemán J, Nos P.

Rev Iberoam Micol. 2009 Sep 30;26(3):213-7. doi: 10.1016/j.riam.2009.01.001. Epub 2009 Jul 26. Spanish.

PMID:
19635442
17.

Listeria monocytogenes infection in Crohn's disease treated with adalimumab.

Willson KJ, Jacob A, Shetti MP, Bhatia R, Yee K, Osler W.

Med J Aust. 2012 Oct 15;197(8):466-7. No abstract available.

PMID:
23072245
18.

Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.

Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T.

Clin Microbiol Infect. 2006 Dec;12(12):1151-3.

19.

Commentary: infliximab or adalimumab in Crohn's disease?

Sprakes MB, Hamlin PJ.

Aliment Pharmacol Ther. 2012 Aug;36(4):398. doi: 10.1111/j.1365-2036.2012.05167.x. No abstract available.

20.

Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease.

Zella GC, Weinblatt ME, Winter HS.

J Pediatr Gastroenterol Nutr. 2009 Sep;49(3):355-8. doi: 10.1097/MPG.0b013e3181837289. No abstract available.

PMID:
19516196

Supplemental Content

Support Center